Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity (Q36388538)

13 August 2017

Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity (English)

1 reference

13 August 2017

3

James L Gulley

1 reference

13 August 2017

Ravi A Madan

1

1 reference

13 August 2017

Christopher R Heery

series ordinal

2

1 reference

13 August 2017

language of work or name

1 reference

1 October 2012

1 reference

13 August 2017

1 reference

13 August 2017

1

1 reference

13 August 2017

7

1 reference

13 August 2017

1167-1168

1 reference

Immunotherapy for Prostate Cancer: Recent Advances, Lessons Learned, and Areas for Further Research

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494633

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494633

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494633

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494633

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494633

Multiple costimulatory modalities enhance CTL avidity

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494633

CTLA-4: new insights into its biological function and use in tumor immunotherapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494633

Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494633

Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

21 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23170267

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23170267

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4161/ONCI.20591

1 reference

13 August 2017

1 reference

13 August 2017

PubMed publication ID

23170267

1 reference